News
Global Cannabis News & Analysis | Business of Cannabis
News · page 6
- Medical Cannabis
Cannabis Use Among Teens Flat After German Partial Legalisation, But Medical Market Continues Rapid Expansion
Germany’s Cannabis Act (CanG) has not led to an increase in use among young people, according to new peer-reviewed research adding to the growing body of evidence contradicting the harms predicted by the reform’s critics.
- Hemp Industry
Bipartisan Bill Seeks to Overturn Intoxicating Hemp Ban and Regulate Multi-Billion Dollar Sector
The US intoxicating hemp market, thought to be worth around $28bn in annual sales, could yet be saved from a devastating ban set to be implemented in a matter of months.
- Opinion
Patients First: What Training the Police Taught Me About Medical Cannabis
As new national guidance instructs officers to treat medical cannabis users as patients first, James Duckenfield, CEO of Glass Pharms, reflects on what training police forces has taught him about the gap between the law and the general understanding of the legal landscape, and how the industry as a whole can help close it.
- Medical Cannabis
Measuring What Matters: Why Outcomes Will Decide the Future of Cannabis Medicine
The UK medical cannabis sector has spent seven years arguing for access.
- Pharmaceutical
Ananda Pharma Doses First Patient in NIHR-Backed CIPN Trial
Ananda Pharma has dosed the first patient in the ACTiON trial, a Phase 2 NIHR-funded study evaluating MRX1, the company’s proprietary CBD-based oral solution, as a treatment for chemotherapy-induced peripheral neuropathy (CIPN), a debilitating nerve-damage condition caused by chemotherapy for which no effective therapies currently exist.
- US & Canada
DEA Rescheduling Hearing Closes as States’ Own Witness Concedes Regulation Reduces Crime
The Drug Enforcement Administration’s (DEA) administrative hearing on cannabis rescheduling saw both sides make their closing arguments on Wednesday, July 15, bringing the 17-day proceedings to a broadly positive close.
- US & Canada
US Rescheduling Hearing Nears End as Opposition’s Own Witness Acknowledges Cannabis Fits Schedule III Standard
Tomorrow (July 15, 2026) the landmark administrative hearing on US cannabis rescheduling will come to a close.
- Medical Cannabis
Curaleaf Becomes First to Register Cannabis Preparations Under Spain’s New Medical Framework
Spain’s medicines regulator has officially approved the first two oil-based preparations as part of its recently approved national medical cannabis scheme.
- Pharmaceutical
World’s Largest CBD Insomnia Trial Could Hand Avecho an Australian Monopoly
The world’s largest clinical trial on cannabidiol (CBD) as a treatment for insomnia has been given the green light to complete its Phase III trial, transforming the fortunes of Avecho Biotechnology, and potentially the lives of insomnia sufferers worldwide.
- Patient Access
Germany Bans Cannabis Flowers from GKV and Mandates Six-Month Trial for Extracts
Germany has today voted to ban medical cannabis flower from its statutory health insurance scheme, in a controversial move critics say will have an outsized impact on the ‘seriously ill’.
- Clinical Research
Why Medical Companies Win Rescheduling, Whatever Happens to Adult-Use
This week, what is perhaps the most consequential hearing in the history of the US, and indeed the global cannabis industry, is taking place in Arlington, Virginia.
- Medical Cannabis
Cannabis Health Announces Two-City Symposium Series Across Frankfurt and London This Autumn
Cannabis Health, the UK’s leading medical cannabis news and education platform, has announced the launch of two autumn events designed for healthcare professionals, prescribers, and industry operators working at the frontline of medical cannabis practice across Europe.
